Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia.
Claudia Maribel Luna-Aguirre1, Margarita de la Luz Martinez-Fierro2, Fermín Mar-Aguilar3
1Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey NL, México.
Cancer Biomarkers : Section a of Disease Markers
|September 26, 2015
Summary
Plasma microRNA (miRNA) profiling identified hsa-miR-511 as a sensitive and specific biomarker for detecting B-acute lymphoblastic leukemia (B-ALL). This finding may aid in disease detection and monitoring treatment response.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Acute lymphoblastic leukemia (ALL) is a heterogeneous cancer with diverse genetic and molecular alterations.
- MicroRNA (miRNA) expression signatures are frequently altered in ALL, suggesting their role in leukemogenesis.
Purpose of the Study:
- To perform and validate plasma miRNA expression profiling.
- To identify potential miRNAs involved in the development of B-acute lymphoblastic leukemia (B-ALL).
Main Methods:
- Plasma samples from 39 B-ALL patients and 7 healthy controls were analyzed using TaqMan Low Density Array (TLDA) plates.
- Differential miRNA expression was validated using quantitative real-time PCR.
Main Results:
- Seventy-seven circulating miRNAs were found to be differentially expressed between B-ALL patients and controls.
- hsa-miR-511 demonstrated high diagnostic accuracy (Area Under Curve = 1, 100% sensitivity and specificity) for distinguishing B-ALL.
Conclusions:
- Circulating hsa-miRNA-511 levels offer a highly sensitive and specific method for B-ALL detection.
- hsa-miRNA-511 may serve as a valuable biomarker for monitoring disease progression, therapeutic response, and identifying therapeutic targets in B-ALL.
